News

15.03.09 22:45 Age: 1 yrs

Ipsogen announces the CE marking of its “ProfileQuant® WT1” kit

Category: Leukemia Leukemia

 

  • WT1 is a valuable biomarker in the prognosis and follow-up of Acute Myeloid Leukemia (AML) patients.
  • The ProfileQuant® WT1 kit was developed and validated in the context of an international collaborative study coordinated by the European Leukemia Network (ELN) consortium.
  • With its WT1 kit, Ipsogen continues its CE marking strategy and confirms its leadership position in molecular diagnosis of leukemia.

More

<- Back to: Ipsogen News List